Non-donor specific anti-human leukocyte antigen (HLA) antibodies are not associated with poor outcome in hematopoietic stem cell transplant recipients
| Autor: | Jeffrey R. Andolina, Michael W. Becker, Angela Busacco, R. Walia, Jane L. Liesveld, Myra Coppage, Andrea Baran, Jamie Oliva |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine medicine.medical_treatment Immunology Graft vs Host Disease Human leukocyte antigen Hematopoietic stem cell transplantation Antibodies 03 medical and health sciences 0302 clinical medicine HLA Antigens medicine Humans Transplantation Homologous Immunology and Allergy Hla antibodies Progression-free survival Retrospective Studies biology business.industry Histocompatibility Testing Hematopoietic Stem Cell Transplantation Hematopoietic stem cell Retrospective cohort study General Medicine Middle Aged Tissue Donors 030104 developmental biology medicine.anatomical_structure Histocompatibility Cohort biology.protein Female Antibody business 030215 immunology |
| Zdroj: | Human Immunology. 81:407-412 |
| ISSN: | 0198-8859 |
| DOI: | 10.1016/j.humimm.2020.05.006 |
| Popis: | Testing for anti-human leukocyte antigen (HLA) antibodies has now become standard practice in allogeneic hematopoietic stem cell transplantation (HSCT), and anti-HLA antibodies (both donor specific and non-donor specific) are being identified and have many potential consequences. Most studies suggest that donor-specific HLA antibodies lead to adverse outcomes, though little is reported on non-donor specific anti-HLA antibodies. We present the results of a retrospective cohort analysis of 157 patients who received HSCT at the University of Rochester over a period of four years. We identified 45 patients (28.7%) who had detectable anti-HLA antibodies, while only one patient (0.6%) had donor-specific anti-HLA antibodies. Patients with prior pregnancies and multiple transfusions were at increased risk to develop antibodies. In our cohort, the presence of non-donor specific anti-HLA antibodies did not significantly impact overall survival, progression free survival, graft failure, or transplant-related mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect